Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Agostini, C.
Right arrow Articles by Gurrieri, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agostini, C.
Right arrow Articles by Gurrieri, C.
The Proceedings of the American Thoracic Society 3:357-363 (2006)
© 2006 The American Thoracic Society

Chemokine/Cytokine Cocktail in Idiopathic Pulmonary Fibrosis

Carlo Agostini and Carmela Gurrieri

Department of Clinical and Experimental Medicine, Clinical Immunology and Hematology Branches, Padua University School of Medicine, Padua, Italy

Correspondence and requests for reprints should be addressed to Carlo Agostini, M.D., Dipartimento di Medicina Clinica e Sperimentale, Università di Padova, Immunologia Clinica and Ematologia, Via Giustiniani 2, 35128 Padova, Italy. E-mail: carlo.agostini{at}unipd.it

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible fibrosing lung disease of unknown etiology and with an unfavorable outcome, leading ultimately to death due to respiratory failure. To date, no treatment strategies have been effective in modifying the natural course of IPF and its fatal outcome. The aberrant parenchymal remodeling is characterized by the expansion of fibroblasts/myofibroblasts, which form characteristic subepithelial foci, and by the abnormal deposition of extracellular matrix in the lung parenchyma. Although the pathophysiology underlying this disease has not yet been fully elucidated, animal models of pulmonary fibrosis have provided contributions in dissecting the molecular basis of this disease, focusing on the role of cytokines and chemokines as important pathogenetic mediators of lung fibrosis. Starting with the data obtained from animal models, this article provides a comment on a number of findings that suggest the possible role of the chemokine/cytokine system in the pathogenesis of IPF.

Key Words: idiopathic pulmonary fibrosis • cytokine • chemokine • bleomycin




This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
F. Saito, S. Tasaka, K.-i. Inoue, K. Miyamoto, Y. Nakano, Y. Ogawa, W. Yamada, Y. Shiraishi, N. Hasegawa, S. Fujishima, et al.
Role of Interleukin-6 in Bleomycin-Induced Lung Inflammatory Changes in Mice
Am. J. Respir. Cell Mol. Biol., May 1, 2008; 38(5): 566 - 571.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. E. Milam, V. G. Keshamouni, S. H. Phan, B. Hu, S. R. Gangireddy, C. M. Hogaboam, T. J. Standiford, V. J. Thannickal, and R. C. Reddy
PPAR-{gamma} agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis
Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L891 - L901.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. Marchal-Somme, Y. Uzunhan, S. Marchand-Adam, M. Kambouchner, D. Valeyre, B. Crestani, and P. Soler
Dendritic Cells Accumulate in Human Fibrotic Interstitial Lung Disease
Am. J. Respir. Crit. Care Med., November 15, 2007; 176(10): 1007 - 1014.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
T. M. Maher, A. U. Wells, and G. J. Laurent
Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?
Eur. Respir. J., November 1, 2007; 30(5): 835 - 839.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. J. Scotton and R. C. Chambers
Molecular Targets in Pulmonary Fibrosis: The Myofibroblast in Focus
Chest, October 1, 2007; 132(4): 1311 - 1321.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
N. M. Patel, D. J. Lederer, A. C. Borczuk, and S. M. Kawut
Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Chest, September 1, 2007; 132(3): 998 - 1006.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
E. M. Pierce, K. Carpenter, C. Jakubzick, S. L. Kunkel, H. Evanoff, K. R. Flaherty, F. J. Martinez, G. B. Toews, and C. M. Hogaboam
Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21
Eur. Respir. J., June 1, 2007; 29(6): 1082 - 1093.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
E. M. Pierce, K. Carpenter, C. Jakubzick, S. L. Kunkel, K. R. Flaherty, F. J. Martinez, and C. M. Hogaboam
Therapeutic Targeting of CC Ligand 21 or CC Chemokine Receptor 7 Abrogates Pulmonary Fibrosis Induced by the Adoptive Transfer of Human Pulmonary Fibroblasts to Immunodeficient Mice
Am. J. Pathol., April 1, 2007; 170(4): 1152 - 1164.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
S. M. Studer and N. Kaminski
Towards Systems Biology of Human Pulmonary Fibrosis
Proceedings of the ATS, January 1, 2007; 4(1): 85 - 91.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Thoracic Society.